Percheron Therapeutics continues to advance Duchenne treatment
–News Direct– Percheron Therapeutics Ltd (ASX:PER) managing director and CEO James Garner sits down with Proactives Jonathan Jackson for a comprehensive update of the company and its focus on treating rare diseases, including the advancement of its lead program, ATL1102. Read more